254 related articles for article (PubMed ID: 30964170)
21. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
[TBL] [Abstract][Full Text] [Related]
22. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of microRNA miR-101-3p enhances sensitivity to cisplatin via regulation of small interfering RNA (siRNA) Anti-human AGT4D and autophagy in non-small-cell lung carcinoma (NSCLC).
Cui D; Feng Y; Qian R
Bioengineered; 2021 Dec; 12(1):8435-8446. PubMed ID: 34694211
[TBL] [Abstract][Full Text] [Related]
25. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
[TBL] [Abstract][Full Text] [Related]
26. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
27. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.
Yu B; Zheng L; Tang H; Wang W; Lin Y
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396444
[TBL] [Abstract][Full Text] [Related]
28. Restricting extracellular Ca2+ on gefitinib-resistant non-small cell lung cancer cells reverses altered epidermal growth factor-mediated Ca2+ response, which consequently enhances gefitinib sensitivity.
Kim MS; Kim SH; Yang SH; Kim MS
PLoS One; 2020; 15(8):e0238155. PubMed ID: 32841278
[TBL] [Abstract][Full Text] [Related]
29. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
30. Influence of Autophagy Inhibition on Lung Adenocarcinoma Cell Migration and Invasion Ability, and Efficacy of Gefitinib.
Liu Y; Du Y
Technol Cancer Res Treat; 2021; 20():15330338211049000. PubMed ID: 34657484
[TBL] [Abstract][Full Text] [Related]
31. MiRNA-621 inhibits the malignant progression of non-small cell lung cancer via targeting SIX4.
Zhang M; Shi H; Zhang C; Zhang SQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4807-4814. PubMed ID: 31210312
[TBL] [Abstract][Full Text] [Related]
32. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of microRNA-144-3p and its clinical value in non-small cell lung cancer: a comprehensive analysis based on microarray, miRNA-sequencing, and quantitative real-time PCR data.
Chen YJ; Guo YN; Shi K; Huang HM; Huang SP; Xu WQ; Li ZY; Wei KL; Gan TQ; Chen G
Respir Res; 2019 Mar; 20(1):48. PubMed ID: 30832674
[TBL] [Abstract][Full Text] [Related]
34. MiR-542-3p exerts tumor suppressive functions in non-small cell lung cancer cells by upregulating FTSJ2.
Liu B; Li J; Zheng M; Ge J; Li J; Yu P
Life Sci; 2017 Nov; 188():87-95. PubMed ID: 28866101
[TBL] [Abstract][Full Text] [Related]
35. Interaction of FLNA and ANXA2 promotes gefitinib resistance by activating the Wnt pathway in non-small-cell lung cancer.
Cheng L; Tong Q
Mol Cell Biochem; 2021 Oct; 476(10):3563-3575. PubMed ID: 34018148
[TBL] [Abstract][Full Text] [Related]
36. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
Tang X; Jiang J; Zhu J; He N; Tan J
Mol Genet Genomics; 2019 Feb; 294(1):85-93. PubMed ID: 30196354
[TBL] [Abstract][Full Text] [Related]
37. MiRNA-500a-3p inhibits cell proliferation and invasion by targeting lymphocyte antigen 6 complex locus K (LY6K) in human non-small cell lung cancer.
Liao XH; Xie Z; Guan CN
Neoplasma; 2018 Sep; 65(5):673-682. PubMed ID: 30249107
[TBL] [Abstract][Full Text] [Related]
38. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma.
Xiao P; Liu WL
Int J Clin Exp Pathol; 2015; 8(9):10800-7. PubMed ID: 26617792
[TBL] [Abstract][Full Text] [Related]
39. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.
Li X; Zhang X; Yang C; Cui S; Shen Q; Xu S
Cell Cycle; 2018; 17(14):1772-1783. PubMed ID: 30010468
[TBL] [Abstract][Full Text] [Related]
40. LncRNA MITA1 promotes gefitinib resistance by inducing autophagy in lung cancer cells.
Hu J; Dong SW; Pei Y; Wang J; Zhang J; Wei XP
Biochem Biophys Res Commun; 2021 Apr; 551():21-26. PubMed ID: 33714755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
